Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
7h agoDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
8h agoRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
10h agoThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
18h agoBuffalo Potash Files Annual Information Form and New Technical Report
19h agoIonik Announces 30-Day Extension of Senior Debt Facility
Innoviva, Inc. logo

Innoviva, Inc.

About

22.46USD+0.26 +1.17%
Closed • Updated at 21:37 GMT+00:00
Market Cap$1.66B
P/E Ratio3.73
Volume1.19M
Beta-0.02
RSI46.57
Gross Margin71.36%
Health TechnologyPharmaceuticals: Major

Innoviva, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

May 6 2026
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Mar 10 2026
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
Feb 25 2026
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Feb 19 2026
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Dec 12 2025
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Community Chat

Ask AI

Try asking
6ix6ixAIEvents